CMS set the 2027 Part D bid and premium benchmarks and will end the long running Premium Stabilization Demonstration after the 2026 plan year.
Inflation Reduction Act
Just in time for midterm elections, a new RFI seeks public input on Medicare drug pricing negotiations, inflation-based rebates, and supply-chain oversight.
The drug maker says data about individual transactions, including patient, provider, service, and payment details, is needed to meet obligations under the Inflation Reduction Act.
The PBM’s announcement model comes amid growing pressure on the nation’s largest pharmacy benefit managers to abandon opaque pricing structures and comply with expanding federal and state transparency requirements.
Our in-brief roundup of notable stories from the last week.
The rising cost of prescription drugs is a concern for patients, healthcare providers and policymakers, but crafting a solution without undermining industry confidence is tricky.
How the US, EU, UK and Japan are looking to fund innovation, make new policies and set regulation to improve the quality of carbon markets.
CFTC Commissioner Christy Goldsmith Romero and Sacha Sadan, FCA’s Director of ESG, discussed climate policy in front of an international audience in London.